Steady progress in treatment continues the remarkable improvements in survival 1 observed since the modern description of cystic fibrosis (CF). 2, 3 CF transmembrane regulator (CFTR) gene sequencing demonstrated that CFTR protein dysfunction underlies clinical disease. [4] [5] [6] Progressive pulmonary and GI diseases characterize classic CF disease observed over centuries 3 and cause early mortality. 1, 7 Increased survival time, milder disease, and knowledge of a specific, disease-causing, abnormal or absent protein facilitate bench and clinical investigations that expand the list of outcomes directly attributable to CFTR dysfunction. Recent development of mutation-specific modulators of CFTR protein synthesis [8] [9] [10] [11] [12] suggests the possibility of directly treating new primary manifestations.
Defective CFTR expression in the brain may lead to detectable abnormalities. [13] [14] [15] Dysfunctional CFTR protein in the retina 16, 17 and anterior hypothalamus [18] [19] [20] may phase shift and reduce the adaptability of the master circadian clock, 21 adversely affecting health, [22] [23] [24] [25] [26] [27] social functioning, [28] [29] [30] [31] and quality of life. 22, [32] [33] [34] [35] Because sleep phase delay is commonly associated with circadian phase delay, we performed a pilot study of sleep phase using noninvasive low-cost, but effective, tools. We hypothesize that sleep phase delay may be a direct clinical manifestation of CFTR dysfunction in the CNS.
Methods

Participants
With University of Utah Investigational Review Board approval (IRB_00005311) and informed consent, we serially recruited adult patients with CF during outpatient visits or hospitalizations for acute pulmonary exacerbations. We recorded age, height, weight, sex, race, ethnicity, CF genotype, and FEV 1 . 36- 38 We normalized FEV 1 to FEV 1 % predicted using National Health And Nutrition Examination Survey (NHANES) III 39 and Global Lung Initiative (GLI) equations. 40 We counted acute pulmonary exacerbations requiring hospitalization in the year prior to study enrollment. At our institution, we diagnose acute pulmonary exacerbations and hospitalize for at least one symptom and one objective finding of acutely worsened lung disease. 41 We do not hospitalize patients with increased symptoms only or objective findings only and did not count those episodes as exacerbations.
We recruited volunteers without CF from the University of Utah Medical Center and local communities. We collected age, height, sex, race, and ethnicity and deidentified the data on collection.
Sleep Phase Evaluation
Till Roenneberg provided permission to use the Munich Chronotype Questionnaire (MCTQ) 42 for research purposes (personal e-mail communication, March 22, 2012 with reconfirmation February 10, 2017). All participants completed the unaltered latest version of the MCTQ, 42 which asks for information concerning bedtime, sleep-onset, and wake times and minutes needed to fall asleep on nights before work and on free days. A lack of obligations requiring specific wake times defines free days. 43 To prevent confusion, we taught participants the definitions used by Dr Roenneberg 42 : (1) sleep-onset time is the time a participant gets into bed (bedtime) plus the time needed to fall asleep (sleep latency) and (2) wake time is the time that a participant becomes awake and not the time that a participant gets out of bed.
Statistical Analysis
We calculated summary statistics. Using sleep-onset and wake times, we estimated midsleep time (the standard single clock time that describes the extent of sleep phase delay or advancement and best correlates with dim light melatonin onset or onset of true biological night) 44 and sleep duration (the maximal possible total time asleep from sleep onset to wake time) on the night prior to a free day. 43 We compared basic characteristics between patients and volunteers using t tests 45 and compared sleep onset, midsleep, and wake times as well as sleep latency and duration using linear regression. Using multivariable linear regression adjusted for age, sex, and height, we performed backward selection based on Wald test P values of each explanatory variable to determine the most parsimonious model for each of the sleep measurements. We performed multivariable linear regressions of each of the five sleep phase measurements, with sleeponset time as the independent variable of main interest adjusted for age, sex, and height with backward selection. With models involving only patients with CF, we performed forward selection with FEV 1 % predicted, number of acute pulmonary exacerbations in the year prior to administration of the MCTQ, weight, height, and F508del homozygous status to explore relationships between the main characteristics of CF that predict survival 7 and sleep phase. With each selection step in each multivariable model, we examined the stability of coefficients, SEs, and P values. For models with acute pulmonary exacerbations as the outcome, we used quasi-Poisson regression because the data were not clearly Poisson in dispersion. Because all participants live in the Salt Lake City area and participated during spring, summer, and fall when daylight hours are longest in Utah, we did not adjust for latitude, longitude, or MCTQ administration date. We used the R statistical system for all analyses. 46 
Results
Participants
We recruited 47 patients with CF and 50 volunteers without CF. We discarded two questionnaires from patients and two from volunteers because of incompleteness. Study groups had the same frequencies regarding sex, race, and ethnicity. All were young adults, but there were small differences in distribution of age and height (Table 1 , e- Fig 1) . All participants were white chestjournal.org except one Hispanic female with CF, consistent with the racial distribution of CF in Utah.
Sleep Analyses
Univariable linear regressions showed that patients with CF had significantly later sleep onset and midsleep and wake times and longer sleep latency and duration than did volunteers without CF (Table 2 ). Multivariable linear regressions adjusted for age, sex, and height gave similar estimates ( Table 3) .
Independent of CF diagnosis, increasing age significantly moved sleep onset, midsleep, and wake times to earlier in the night while lengthening average sleep latency (e-Table 1A-D) but had no significant effect on sleep duration. Female subjects had a later sleep onset (by 53 minutes) (e -Table 1A ) and a shorter sleep duration (by 42 minutes) (e-Table 1E) on average. Greater height was significantly associated only with later time of midsleep (e-Table 1B).
We evaluated variation among subjects that was associated with the choice of earlier or later bedtimes. For every hour sleep onset was later (Table 4) , patients with CF had a 7.51-min prolongation in sleep latency (95% CI, 3.75 min; 11.27 min) and nearly an hour delay in both midsleep (95% CI, 0.74 h; 0.97 h) and wake times (95% CI, 0.48 h; 0.93 h), but the total duration of sleep was shorter by about 18 min (95% CI, -3.76 min; -31.28 min). Adjustment by patient age was significantly associated with sleep latency, midsleep, and wake times and sleep duration (e -Table 2A-D) . In contrast, a 1-h delay in sleep onset in volunteers without CF was not associated with sleep latency or wake time but was associated with a midsleep time 38 min later on average (95% CI, 22.84 min; 40.27 min) and a sleep duration that was shorter by 45 min (95% CI, -62.40 min; -27.60 min). Age adjustments had no significant effect in volunteers without CF, and sex and height adjustments had no significant effects for either patients with CF or volunteers without CF.
Sleep latency effects were prolonged and other sleep effects were decreased with each additional year of age (e- Table 2 ). Midsleep and wake times and sleep latency Estimates and SE are in hours except as noted. See Table 2 and duration associated with later sleep onset were not significantly associated with sex or height.
Using either linear or quasi-Poisson regression, as appropriate, we found no significant relationships between sleep latency or duration or sleep-onset, midsleep, or wake times with FEV 1 % predicted, number of acute pulmonary exacerbations in the year prior to administration of the MCTQ, or weight (Fig 1) in patients with CF. There were no significant associations with F508del homozygous state. Using univariable quasi-Poisson regression, we found that the number of acute pulmonary exacerbations was strongly associated with lung disease severity in patients with CF (Fig 2) . Multivariable models adjusted for age, sex, and height failed to uncover significant associations between any sleep measurements and FEV 1 % predicted, number of acute pulmonary exacerbations, or weight. Using NHANES III or GLI equations for normalization of FEV 1 produced nearly identical values of FEV 1 % predicted (e -Fig 2, e- Table 3 ) with no effect on results (Table 1, 
Discussion
We performed a pilot study examining sleep timing and duration among patients with CF compared with volunteers without CF. We found that adults with CF have markedly delayed sleep phase and prolonged sleep latency and duration (Table 2) . Study patients had a wide range of disease, from normal lung function and no acute pulmonary exacerbations in the year prior to MCTQ administration to an FEV 1 approximately 20% of predicted and more than five exacerbations (Fig 2) , providing the opportunity to detect relationships with measurements of sleep phase. In fact, we found no relationship between any sleep phase measurement and FEV 1 % predicted, number of prior acute pulmonary exacerbations, or weight (Fig 1, e-Fig 3) , the three major determinants of survival in CF. 7 The marked differences in sleep phase measurements among patients with CF compared with control volunteers without CF (Table 3) support the possibility that CF is associated with circadian rhythm delay, and the lack of significant associations with disease severity markers is consistent with the possibility that sleep phase delay is a novel clinical manifestation of circadian cycle abnormality due to CFTR dysfunction in the CNS. 21 Later sleep onset was associated with longer sleep latency and later wake times in patients with CF, relationships not seen in volunteers without CF (Table 4 ). All study participants had decreased sleep duration associated with later sleep onset; however, the effect was twice as large in volunteers. The differences between our study groups underscore the marked differences in sleep phase associated with CF; however, these findings cannot distinguish between an effect due to the clinical biology of CFTR dysfunction or differing societal influences associated with chronic CF disease.
Sleep findings were stable after adjustments for age, sex and height. After selection procedures, most of the multivariable models retained age as a significant covariate (e -Tables 1A-D, 2A-D) . Some models retained female sex (e- Table 1A , 1E) and increasing height (e -Table 1B) . Similar age-, sex-, and height-related effects have been described and provide reassurance that results derived from the control volunteers without CF are consistent with prior large population studies of sleep, particularly those using the MCTQ, 37 and provide a reasonable basis for comparison to discover CF-specific differences in sleep phase.
A circadian cycle abnormality may be a simple phase shift that causes later bedtimes and wake times relative to a typical circadian cycle. 47 More complex circadian See Table 2 legend for expansion of abbreviations. a Estimates for patients with CF are for the effects of later sleep-onset times adjusted for age; sex and height adjustments were not significant. Estimates of effects of age are shown in e- Table 2 . Estimates for effects of later sleep-onset times in volunteers without CF are unadjusted because age, sex, and height were not significant.
chestjournal.org abnormalities may include non-24-hour cycles or cycles that are associated with irregular sleep-wake patterns. Determination of the circadian cycle abnormality types that patients with CF may have will require more extensive methods than used in the current study.
A circadian phase shift and accompanying sleep phase delay need not cause an intrinsic physiological abnormality. However, such a phase delay interferes with daily life activities that begin in the morning, for example, 8 AM start times for school or work. Individuals with severe phase delays may experience academic failures 48,49 because of the inability to attend and perform well in morning classes. These individuals may be unable to hold jobs except those that start in the afternoon and continue through the evening or night, a circumstance that may lead to economic consequences or limit social interactions with friends or families in afternoon or evening settings. Individuals with sleep phase delay who try to work typical daytime hours may experience a form of shift work disorder that can lead to a variety of physical ailments. A B Figure 1 -Sleep phase measurements and clinical data for patients with cystic fibrosis (CF). A, We found no relationship between lung function, prior acute pulmonary exacerbations, or weight with sleep latency or total sleep duration in patients with CF. Compared with control subjects, patients with CF had longer sleep latency that was significant without adjustment and prolonged sleep duration that was borderline in significance (Table 2) . However, both latency and duration were significantly longer in patients with CF after adjustment for age, sex, and height (Table 3) . B, Timing of sleep onset, midsleep, and wake times were independent of FEV 1 % predicted, number of acute pulmonary exacerbations in the prior year, and weight among patients with CF. Volunteers without CF had earlier times for all three sleep events. The differences were significant without adjustment (Table 2) , and the associations were strengthened after adjustments for age, sex, and height, as appropriate (Table 3 , e-Table 1A-C). APE ¼ acute pulmonary exacerbation; CF ¼ cystic fibrosis.
Our study was a pilot and thus subject to potential shortcomings. We used serial recruitment and thus might have enrolled a nonrepresentative patient population with CF, resulting in poor generalizability of our results. However, the wide ranges of FEV 1 % predicted and prior acute pulmonary exacerbation counts (Fig 2) and the broad range of sleep phase findings (Tables 2-4 ) provide reassurance that the lack of significant associations was not due to a lack of variation in severity of measurements. We performed analyses twice involving FEV 1 % predicted normalized with NHANES III 39 and GLI equations. 40 Results were similar ( Table 1 , e-Figs 2-4, e- Table 3) showing that for the adults with CF, the choice of equation had no impact. The number of study participants included > 20% of our adult CF center population, suggesting that our results were not spurious because of a few unusual individuals. We might have undercounted acute pulmonary exacerbations if care was obtained outside our institution. However, most hospitalizations elsewhere result in transfers to our CF center, the only one accredited for adults in Utah. We internally audit charts to prevent underreporting of pulmonary exacerbations, although we cannot exclude the possibility that some patients avoid care altogether when ill. Readers should note that we define acute pulmonary exacerbations of CF in a way that depends only on data available at the time of evaluation to facilitate prospective application at the point of care. 41 That definition does not require calculating pulmonary exacerbation or pulmonary exacerbation risk scores 52, 53 nor does it consider any retrospective criterion 54 that may affect the interpretation of our results.
Our evaluation of sleep phase changes relative to a control group of volunteers without CF controlled for societal behaviors regarding sleep patterns. We did not, however, explore differences in the use of electronic devices that allow social media interactions while adhering to infection control guidelines. These devices may produce blue light, which can phase shift the circadian clock. 55 Future investigation might consider whether patients with CF use these devices more frequently than do the volunteers without CF. There were minor differences in the demographics of control subjects compared with study patients. Control volunteers were younger and taller (Table 1) . However, absolute differences were small, were adjusted for in multivariable analysis, and ultimately had no impact on results or their interpretation.
We did not measure salivary melatonin levels or ask participants to wear actigraphs to ascertain the onset and duration of biological night 22 in the study population due to the cost of measurements and equipment and the 6-h time requirement to collect samples. 34, 56, 57 Actigraph and additional sleep questionnaire data might confirm that coughing and poor sleep quality do not explain sleep phase delay. 58 Nevertheless, our primary goal was to generate sufficient evidence to support the overall hypothesis that sleep phase delay may be a direct clinical manifestation of CFTR dysfunction in the CNS. Treating such a sleep phase delay might substantially improve health and well-being. Our study accomplished this goal and provides the data necessary to plan a more extensive and thorough future investigation, perhaps involving a multicenter design with melatonin measurements and actigraph recordings along with a more extensive assessment of the impact of sleep phase delay on quality of life in patients with CF.
This study shows that sleep phase delay is common and severe in patients with CF. These preliminary findings already suggest potential low-risk accommodations such as afternoon appointments or medication schedules that chestjournal.org may improve adherence to clinic visits and treatments for patients having difficulty with early wake times. The evidence presented supports further investigation to better understand biological underpinnings of the clinical findings and societal functioning and quality of life. Confirmation of sleep phase delay with a better understanding of subsequent clinical impacts would reveal a new manifestation of CFTR dysfunction that itself could be a new target for treatment, particularly among patients with normal or minimally diseased lungs who currently lack a formal indication for CFTR modulator treatment.
